This is a profoundly important point. I want to highlight it:
For many patients with obesity, disordered eating behaviors serve as coping mechanisms for underlying anxiety, depression, trauma, or emotional dysregulation. When GLP-1 RAs remove the food-seeking behavior, the underlying condition can surface — sometimes dramatically.
This is why I advocate for psychological support as a standard component of GLP-1 therapy, not an afterthought. A therapist familiar with eating disorders and weight management can be invaluable during this transition.
Additionally, the FDA does require monitoring for suicidal ideation with GLP-1 RAs as a class. While the data has NOT shown an increased risk of suicidality in trials, the regulatory concern reflects the acknowledgment that these drugs affect brain function. If anyone experiences suicidal thoughts, please reach out to the 988 Suicide and Crisis Lifeline immediately.